Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
PLoS One ; 11(2): e0148429, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26894921

RESUMO

BACKGROUND: Most studies provide evidence that the skin flush response to nicotinic acid (niacin) stimulation is impaired in schizophrenia. However, only little is known about niacin sensitivity in the ultra-high risk (UHR) phase of psychotic disorders. METHODS: We compared visual ratings of niacin sensitivity between adolescents at UHR for psychosis according to the one year transition outcome (UHR-T n = 11; UHR-NT n = 55) with healthy controls (HC n = 25) and first episode schizophrenia patients (FEP n = 25) treated with atypical antipsychotics. RESULTS: Contrary to our hypothesis niacin sensitivity of the entire UHR group was not attenuated, but significantly increased compared to the HC group, whereas no difference could be found between the UHR-T and UHR-NT groups. As expected, niacin sensitivity of FEP was attenuated compared to HC group. In UHR individuals niacin sensitivity was inversely correlated with omega-6 and -9 fatty acids (FA), but positively correlated with phospholipase A2 (inPLA2) activity, a marker of membrane lipid repair/remodelling. CONCLUSIONS: Increased niacin sensitivity in UHR states likely indicates an impaired balance of eicosanoids and omega-6/-9 FA at a membrane level. Our findings suggest that the emergence of psychosis is associated with an increased mobilisation of eicosanoids prior to the transition to psychosis possibly reflecting a "pro-inflammatory state", whereas thereafter eicosanoid mobilisation seems to be attenuated. Potential treatment implications for the UHR state should be further investigated.


Assuntos
Niacina/metabolismo , Transtornos Psicóticos/epidemiologia , Transtornos Psicóticos/metabolismo , Pele/metabolismo , Adolescente , Adulto , Ativação Enzimática , Ácidos Graxos/metabolismo , Feminino , Rubor/induzido quimicamente , Humanos , Espaço Intracelular/metabolismo , Masculino , Niacina/farmacologia , Fosfolipases A2/metabolismo , Transtornos Psicóticos/etiologia , Risco , Pele/efeitos dos fármacos , Pele/patologia , Adulto Jovem
2.
Artigo em Inglês | MEDLINE | ID: mdl-26260538

RESUMO

BACKGROUND: Oxidative stress and impaired antioxidant defenses are reported in schizophrenia and are associated with disturbed neurodevelopment, brain structural alterations, glutamatergic imbalance, increased negative symptoms, and cognitive impairment. There is evidence that oxidative stress predates the onset of acute psychotic illness. Here, we investigate the effects of omega-3 PUFA on the vitamin E and glutathione antioxidant defense system (AODS). METHOD: In 64 help-seeking UHR-individuals (13-25 years of age), vitamin E levels and glutathione were investigated before and after 12 weeks of treatment with either 1.2g/d omega-3 (PUFA-E) or saturated fatty acids (SFA-E), with each condition also containing 30.4mg/d alpha-tocopherol to ensure absorption without additional oxidative risk. RESULTS: In multivariate tests, the effects on the AODS (alpha-tocopherol, total glutathione) were not significantly different (p=0.13, p=0.11, respectively) between treatment conditions. According to univariate findings, only PUFA-E caused a significant alpha-tocopherol increase, while PUFA-E and SFA-E caused a significant gamma- and delta-tocopherol decrease. Total glutathione (GSHt) was decreased by PUFA-E supplementation. CONCLUSION: Effects of the PUFA-E condition on the vitamin E and glutathione AODS could be mechanisms underlying its clinical effectiveness. In terms of the vitamin E protection system, PUFA-E seems to directly support the antioxidative defense at membrane level. The effect of PUFA-E on GSHt is not yet fully understood, but could reflect antioxidative effects, resulting in decreased demand for glutathione. It is still necessary to further clarify which type of PUFA/antioxidant combination, and in which dose, is effective at each stage of psychotic illness.


Assuntos
Antioxidantes/análise , Ácidos Graxos Ômega-3/administração & dosagem , Transtornos Psicóticos/tratamento farmacológico , Vitamina E/análise , alfa-Tocoferol/análise , Adolescente , Adulto , Antioxidantes/administração & dosagem , Estudos Transversais , Ácidos Graxos/administração & dosagem , Ácidos Graxos/farmacologia , Ácidos Graxos Ômega-3/farmacologia , Feminino , Humanos , Estudos Longitudinais , Masculino , Análise Multivariada , Resultado do Tratamento , Vitamina E/administração & dosagem , Adulto Jovem , alfa-Tocoferol/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA